Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ARMP
STRONG SELLArmata Pharmaceuticals, Inc. · Healthcare · United States · $171M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections. The company leverages its proprietary phage-specific platform and state-of-the-art manufacturing facility to target high-unmet-need respiratory and systemic infections. Armata operates as a niche pioneer in the phage therapy sector, backed by strategic partnerships and a robust IP portfolio.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 2.2M | 2.8M | — |
| EPS | -1.08 | -1.91 | -0.52 | -4.80 | — | -7.78 | -3.81 | -1.34 | — |
| Shares | 36.1M | 36.1M | 36.2M | 36.4M | +0.8% | 36.7M | — | — | — |
| Debt | 48.8M | 120.4M | 126.5M | 288.0M | 80.7% | 373.7M | — | — | — |
| Equity | 36.1M | -32.1M | -48.0M | -218.6M | — | — | — | — | — |
| Op CF | -32.5M | -47.4M | -37.6M | -25.8M | — | -24.0M | — | — | — |
| Inv CF | -2.2M | -8.1M | -1.9M | -0.5M | — | — | — | — | — |
| Fin CF | 44.0M | 54.0M | 35.0M | 25.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ARMP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ARMP | Armata Pharmaceuticals, Inc.(you) | $171M | 3 | STRONG SELL |
| HUMA | Humacyte, Inc. | $168M | 2 | STRONG SELL |
| ALEC | Alector, Inc. | $164M | 6 | STRONG SELL |
| LENZ | LENZ Therapeutics, Inc. | $172M | 7 | STRONG SELL |
| GLSI | Greenwich LifeSciences, Inc. | $191M | 8 | STRONG SELL |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $164M | 9 | STRONG SELL |
| 0HIY.L | Atara Biotherapeutics, Inc. | $161M | 10 | STRONG SELL |
| GUTS | Fractyl Health, Inc. | $123M | 5 | STRONG SELL |
| RANI | Rani Therapeutics Holdings, Inc. | $117M | 2 | STRONG SELL |
| SPRB | Spruce Biosciences, Inc. | $119M | 5 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.6%